In this Alpha Wolf interview with CEO Aras Azadian of Avicanna Inc., we discuss the science behind cannabis, where Avicanna has been focused since the beginning of the Cannabis transformation and acceptance. While many companies focused on recreation, Aras and his team focused on science. That focus is now paying dividends, with Avicann now having an approved drug and a 30 million dollar run rate. Aras and I discuss his tenacity and the wisdom not to take on toxic financing. We talk about potential catalysts in the near term with several potential partners. Aras has assembled a team at Avicanna and established itself as an honest biotech company doing actual research with an exciting pipeline of opportunities. Avicanna Inc. has weathered the storm, getting closer each day to solidifying its leadership position with the backing of real-world data.
Youtube Link
https://youtu.be/bMr3BqKukpM?si=hkIgI5ECdMtfyu3G
